DIA Europe 2025 to Tackle EU Reforms & Global Healthcare Harmonization
DIA, a global non-profit for life sciences professionals, will host DIA Europe 2025 from March 18-20 in Basel, bringing together stakeholders to discuss healthcare system efficiencies, international collaboration, and recent regulatory changes.
DIA Europe 2025, the continent’s leading neutral healthcare conference, will convene over 300 speakers from more than 150 organizations to discuss critical advancements in healthcare. With over 100 topics across 10 content tracks, this year’s program includes reworked themes on clinical trials innovation and global insights to address current challenges. These discussions aim to shape policies that enhance pharmaceutical development and patient care, covering environmental impact, regulatory digitalization, artificial intelligence (AI), and the latest EU pharmaceutical reforms.
The conference will take place from March 18-20 in Basel, Switzerland, bringing together representatives from the European Medicines Agency (EMA), the European Commission, national regulatory bodies, academia, health technology assessment groups, patient advocacy organizations, and more than 200 industry leaders. Their collective insights will contribute to strengthening cross-border healthcare delivery and addressing global health challenges.
A Platform for Healthcare Collaboration and Innovation
“To bridge gaps, drive progress, and create policies that improve patient outcomes, harmonization among all healthcare stakeholders is essential,” said Ania Mitan, DIA’s Senior Vice President and Managing Director for Europe, the Middle East, Africa, and India (EMEAI). “DIA Europe 2025 fosters collaboration by providing a space where diverse perspectives and shared expertise generate meaningful solutions.”
As healthcare systems worldwide face increasing complexities, this event will provide a crucial platform to discuss and develop solutions that optimize regulatory frameworks, enhance patient engagement, and promote digital transformation in medicine. By integrating insights from global health authorities, pharmaceutical leaders, and patient advocacy groups, DIA Europe 2025 will set the stage for actionable policies that can drive long-term improvements in healthcare access and efficiency.
Keynote Speakers and Emerging Technologies
Two distinguished healthcare leaders will deliver keynote presentations on integrating technology with patient care to enhance treatment efficiency. Dr. Peiling Yap, Chief Scientist at HealthAI, will discuss responsible AI implementation to ensure equitable and sustainable healthcare solutions. As AI becomes increasingly embedded in healthcare decision-making, Dr. Yap will highlight the need for ethical considerations, transparency, and fairness in AI-driven medical applications.
Simon Rasalingham, CEO and Chairman of behold.ai, will showcase how emerging diagnostic technologies can revolutionize patient outcomes through early detection and improved treatment strategies. His session will focus on how AI-driven imaging technologies can streamline diagnostics, reduce delays, and enable faster medical interventions.
Policy and Regulatory Discussions
The conference’s DIAmond sessions will address significant developments in European healthcare policy. The EU Regulatory Town Hall will feature insights from EMA Executive Director Emer Cooke, María Jesús Lamas Díaz, Executive Director of the Spanish Agency for Medicines and Medical Devices (AEMPS), and Steffen Thirstrup, EMA’s Chief Medical Officer. These key regulators will discuss how the latest legislative changes will impact the pharmaceutical landscape and what steps need to be taken to harmonize regulatory standards across Europe.
Additional discussions will include industry leaders from Amgen, AstraZeneca, Bayer, GSK, MSD, Roche, Sanofi, and Novartis. These sessions will focus on frameworks for global medicine regulation digitalization, the establishment of sustainability standards, patient engagement advancements, and European healthcare initiatives. As the industry shifts towards increased transparency and patient-centered regulatory approaches, these discussions will highlight best practices and opportunities for global alignment.
Driving Innovation and Inclusion
DIA Europe 2025 will introduce targeted initiatives to foster innovation and inclusivity. A startup accelerator on March 18 will connect emerging companies with regulatory authorities to streamline development pathways. By providing a space for direct dialogue with policymakers, this initiative aims to reduce regulatory barriers and accelerate market entry for groundbreaking healthcare innovations.
Interactive DIAlogue sessions will explore sustainable partnerships and strategies to include underrepresented populations in clinical trials. Ensuring diversity in clinical research is a growing priority for regulatory bodies and pharmaceutical companies alike. These sessions will highlight ways to improve patient recruitment strategies, minimize disparities, and ensure that new treatments are effective for diverse populations.
In addition to scientific and regulatory discussions, the event will emphasize the role of digital transformation in healthcare. Sessions will examine the impact of real-world data (RWD) and real-world evidence (RWE) in regulatory decision-making, showcasing successful case studies where data-driven approaches have led to better healthcare outcomes.
Strengthening Cross-Sector Collaboration
One of the core objectives of DIA Europe 2025 is to encourage multi-stakeholder collaboration. With participation from regulatory agencies, industry leaders, patient advocates, and academia, the event will facilitate cross-sector dialogue to drive innovation and policy alignment. Key discussion areas include:
- The role of AI and digital health tools in streamlining clinical trials and regulatory processes
- How pharmaceutical companies can enhance sustainability practices and reduce their environmental footprint
- The importance of integrating patient perspectives into drug development and approval processes
- Strategies for expanding access to affordable medicines across European and global markets
By bringing these critical topics to the forefront, DIA Europe 2025 will help define the next generation of healthcare policies that prioritize efficiency, sustainability, and patient-centered innovation.
About DIA
DIA is a leading global non-profit life sciences association that fosters collaboration in drug, device, and diagnostics development to improve global health. Founded in 1964 with headquarters in Washington, D.C., and offices in Europe and Asia, DIA provides networking opportunities, educational resources, scientific research publications, and professional development programs to members in over 80 countries. By facilitating dialogue among regulators, industry experts, and patient advocates, DIA plays a crucial role in advancing healthcare innovation and regulatory excellence worldwide.
